Stocks and Investing Stocks and Investing
Fri, November 2, 2018
Thu, November 1, 2018

Charles Duncan Maintained (ACAD) at Buy with Increased Target to $30 on, Nov 1st, 2018


Published on 2024-10-26 10:14:54 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $27 to $30 on, Nov 1st, 2018.

Charles has made no other calls on ACAD in the last 4 months.



There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matteis Paul of "Stifel" Maintained at Hold with Decreased Target to $14 on, Thursday, August 9th, 2018


These are the ratings of the 2 analyists that currently disagree with Charles


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $25 on, Wednesday, October 10th, 2018
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $27 on, Thursday, August 9th, 2018

Contributing Sources